Articles related to ANTIBODY-DRUG CONJUGATES (ADCs)
New Frontline Standard for Urothelial Carcinoma Comes With Questions
Explore the nuanced implications of the FDA’s accelerated approval of enfortumab vedotin plus pembrolizumab for cisplatin-ineligible urothelial carcinoma patients, including questions on optimal treatment duration and adverse effects.
Oncology, Medical August 28th 2023
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL (CME)
Explore the newest developments in lymphoma therapy with the help of this CME program, learn how effective bispecific antibodies and antibody-drug conjugates are, and fine-tune your therapeutic approaches.
Hematology/Oncology July 10th 2023
Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?
Unfolding the Potentials of Anti-TROP2 ADC Therapy in Triple-Negative Breast Cancer Evolving therapeutic paradigms for triple-negative breast cancer (TNBC) are in focus, as esteemed experts highlight the use of novel anti-TROP2 antibody drug conjugates in an enlightening multidisciplinary tumor board.
Oncology, Medical June 8th 2023
A Deep Dive into the Management of AEs Associated with ADCs
HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.
Oncology, Medical January 23rd 2023